1,416
Views
3
CrossRef citations to date
0
Altmetric
Articles

Safety evaluation of long-term temperature controlled whole-body thermal treatment in female Aachen minipig

ORCID Icon, , , , , , , , , & ORCID Icon show all
Pages 165-175 | Received 19 Oct 2020, Accepted 08 Jan 2021, Published online: 12 Feb 2021

References

  • Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat HHS Public Access. Nat Rev Immunol. 2015;15(6):335–349.
  • Hurwitz MD. Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia. 2019;36(sup1):4–9.
  • Nauts HC. Bacterial vaccine therapy of cancer. Dev Biol Stand [Internet]. 1977;38:487–494.
  • Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64(3):529–564.
  • Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperth. 2014;30(8):531–539.
  • Bettaieb A, Wrzal PK, Averill-Bates DA. Hyperthermia: cancer treatment and beyond. cancer treat - Conv Innov approaches. InTech; 2013. DOI:https://doi.org/10.5772/55795
  • Behrouzkia Z, Joveini Z, Keshavarzi B, et al. Hyperthermia: how can it be used? Oman Med J. 2016;31(2):89–97.
  • Atmaca A, Al-Batran SE, Neumann A, et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. Gynecol Oncol. 2009;112(2):384–388.
  • Atanackovic D, Pollok K, Faltz C, et al. Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes. Am J Physiol - Regul Integr Comp Physiol. 2006;290:585–594.
  • Cihoric N, Tsikkinis A, Van Rhoon G, et al. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. Int J Hyperthermia. 2015;31(6):609–614.
  • Mallory M, Gogineni E, Jones GC, et al. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit Rev Oncol Hematol. 2016;97:56–64.
  • Shen RN, Hornback NB, Shidnia H, et al. Whole-body hyperthermia decreases lung metastases in lung tumor-bearing mice, possibly via a mechanism involving natural killer cells. J Clin Immunol. 1987;7(3):246–253.
  • Zhao C, Dai C, Chen X. Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer. Int J Hyperth. 2012;28(8):735–741.
  • Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.
  • Hildebrandt B, Hegewisch-Becker S, Kerner T, et al.; German Interdisciplinary Working Group on Hyperthermia. Current status of radiant whole-body hyperthermia at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'. Int J Hyperthermia. 2005;21(2):169–183.
  • Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol. 2014;41(6):714–729.
  • van der Zee J. Heating the patient: A promising approach? Ann Oncol. 2002;13(8):1173–1184.
  • Datta NR, Kok HP, Crezee H, et al. Integrating loco-regional hyperthermia into the current oncology practice: SWOT and TOWS analyses. Front Oncol. 2020;10:819. Available from: www.frontiersin.org.
  • Werthmöller N, Frey B, Rückert M, et al. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo. Int J Hyperthermia. 2016;32(1):23–30.
  • Multhoff G, Habl G, Combs SE. Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging. Int J Hyperthermia. 2016;32(4):455–463.
  • Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. Adv Drug Deliv Rev. 2020;163–164:84–97.
  • Issels RD, Lindner LH, Verweij J, et al .; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial . JAMA Oncol. 2018;4(4):483–492.
  • Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
  • Roussakow S. The history of hyperthermia rise and decline. Int Clin Hyperth. 2013;2013:428027. Available from: https://www.hindawi.com/journals/cpis/2013/428027/.
  • van der Zee J, Vujaskovic Z, Kondo M, et al. The Kadota Fund International Forum 2004-clinical group consensus. Int J Hyperthermia. 2008;24(2):111–122.
  • Hegewisch-Becker S, Gruber Y, Corovic A, et al. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study . Ann Oncol. 2002;13(8):1197–1204.
  • Hegewisch-Becker S, Braun K, Otte M, et al. Effects of whole body hyperthermia (41.8 °C) on the frequency of tumor cells in the peripheral blood of patients with advanced malignancies. Clin Cancer Res. 2003;9:2079–2084.
  • Cao YL, Hu XH, Lu YK, et al. Clinical study of chemotherapy combined with whole body microwave hyperthermia in treatment of advanced non-small cell lung cancer. Chinese J. cancer Prev. Treat. 2008;15:927–929.
  • Suvernev A, Ivanov G, Efremov A. et al. whole body hyperthermia at 43. 5-44° C : dreams or reality? necessity of high-level whole body hyperthermia what are possible ways to suppress the activity of trypsin during hyperthermia? Madame Curie Biosci. Database. 2013:6310. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6310/.
  • Colleton C, Brewster D, Chester A, et al. The use of minipigs for preclinical safety assessment by the pharmaceutical industry: results of an IQ DruSafe minipig survey. Toxicol Pathol. 2016;44(3):458–466.
  • Pawlowsky K, Ernst L, Steitz J, et al. The aachen minipig: phenotype, genotype, hematological and biochemical characterization, and comparison to the göttingen minipig. Eur Surg Res. 2017;58(5-6):193–203.
  • Watson AL, Carlson DF, Largaespada DA, et al. Engineered swine models of cancer. Front Genet 2016;7:78. Available from: www.frontiersin.org.
  • Bode G, Clausing P, Gervais F, et al.; Steering Group of the RETHINK Project. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods. 2010;62(3):196–220.
  • Heining P, Ruysschaert T. The use of minipig in drug discovery and development. Toxicol Pathol. 2016;44(3):467–473.
  • Van Der Laan JW, Brightwell J, Mcanulty P, et al. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. 2010. [cited 2020 Jul 24]; Available from: http://www.ema.europa.eu.
  • Gesson-Paute A, Ferron G, Thomas F, et al. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): An experimental study. Ann Surg Oncol. 2008;15(1):339–344.
  • Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: An experimental study. Ann Surg. 2012;256(6):1084–1088.
  • Ferron G, Gesson-Paute A, Classe JM, et al. Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: An experimental study. Gynecol Oncol. 2005;99(2):358–361.
  • Sebeke LC, Rademann P, Maul AC, et al. Feasibility study of MR-guided pancreas ablation using high-intensity focused ultrasound in a healthy swine model. Int J Hyperthermia. 2020;37(1):786–798.
  • Plotzki E, Heinrichs G, Kubícková B, et al. Microbiological characterization of a newly established pig breed, Aachen Minipigs. Xenotransplantation. 2016;23(2):159–167.
  • Díaz M, Becker DE. Thermoregulation: physiological and clinical considerations during sedation and general anesthesia. Anesth Prog. 2010;57(1):25–33.
  • Taylor F, Toh C-H, Hoots K, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(11):1327–1330.
  • Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood Am Soc Hematol. 2009;113:2878–2887.
  • Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367–379.
  • Gounden V, Bhatt H, Jialal I. Renal Function Tests [Internet]. StatPearls. StatPearls Publishing; 2020. [cited 2020 Jul 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29939598.
  • Kalamida D, Karagounis IV, Mitrakas A, et al. Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression. PLoS One. 2015;10(1):e0116021–12.
  • Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. Lancet Publishing Group. 2002;3(8):487–497.
  • Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochem Clin Stud. 1967;20:1351–1381.
  • Yarmolenko PS, Moon EJ, Landon C, et al. Thresholds for thermal damage to normal tissues: An update. Int J Hyperthermia. 2011;27(4):320–343.
  • Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res. 2013;1(4):210–216.
  • Hegyi G, Szigeti GP, Szász A. Hyperthermia versus oncothermia: Cellular effects in complementary cancer therapy. Evidence-Based Complement. Altern. Med. 2013;2013:1–12.
  • van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int. J. Hyperth. Taylor and Francis Ltd. 2016;32(4):446–454.
  • Oei AL, Vriend LEM, Krawczyk PM, et al. Targeting therapy-resistant cancer stem cells by hyperthermia. Int. J. Hyperth. Taylor and Francis. 2017;33(4):419–427.
  • Storm FK, Harrison WH, Elliott RS, et al. Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials. Cancer Res. 1979;39(6 Pt 2):2245–2251.
  • Horsman MR. Tissue physiology and the response to heat. Int J Hyperth. 2006;22(3):197–203.
  • van Rhoon GC, Franckena M, ten Hagen TLM. A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy. Adv Drug Deliv Rev. 2020;163-164:145–156.
  • Madrahimov N, Natanov R, Khalikov A, et al. Warming and cooling device using thermoelectric Peltier elements tested on male mice. Lab Anim. 2020;54(5):443–451.
  • Ragan HA, Gillis MF. Restraint, venipuncture, endotracheal intubation, and anesthesia of miniature swine. Lab Anim Sci. 1975;25(4):409–419.
  • Becker M. Anesthesia in Göttingen miniature swine used for experimental surgery - PubMed. Lab Anim Sci. 1986;36:417–419.
  • Clutton RE, Reed F, Eddleston M, et al. Prolonged anaesthesia in minipigs. Prolong Anaesth Minipigs. 2013:11–15.